LiverHepatitis B virusAntitubercular AgentsHepatitis BHepatitis B Surface AntigensBlood DonorsAdministration, InhalationHepatitis B AntibodiesPan troglodytesCarrier StateHepatitis B Core AntigensHepatitis B e AntigensHepatovirusBronchoalveolar Lavage FluidCapreomycin
Dr. Gerety studies a variety of conditions, mainly focusing on hepatitis B and multidrug-resistant tuberculosis (MDR TB). His research looks at how certain treatments can improve outcomes for patients suffering from these serious infections. For example, he investigates how inhaled capreomycin can effectively target TB bacteria in the lungs while minimizing side effects. Additionally, Dr. Gerety explores the immune response to hepatitis B, examining how the virus interacts with the body’s defenses, and studies interventions like radiation therapy to aid patients recovering from surgical procedures for blocked leg arteries.
Key findings
Inhaled capreomycin delivered through 2-3 doses achieves lung levels 50 to 100 times higher than in blood, effectively killing TB bacteria.
In a study of 21 patients undergoing peripheral arterial bypass, 57% experienced graft blockages within 10 months, although radiation therapy appeared to reduce abnormal tissue growth.
Chronic hepatitis B patients have T-cells present that can attack the virus, but certain antibodies can prolong infection instead of aiding the immune response.
During acute hepatitis B infection, interferon treatment increases HLA class I protein levels on liver cells, which assists in clearing the virus.
In a study of 145 children, 34% were found to have been previously infected with hepatitis A, with infection rates rising significantly with age.
Frequently asked questions
Does Dr. Gerety study tuberculosis?
Yes, Dr. Gerety studies tuberculosis, particularly focusing on treatments for multidrug-resistant strains using inhaled capreomycin.
What treatments has Dr. Gerety researched for hepatitis B?
Dr. Gerety has researched various treatments for hepatitis B, including the effects of interferon therapy and examining how the immune system responds to the virus.
Is Dr. Gerety's work relevant to patients with chronic hepatitis?
Yes, his findings help inform treatment approaches for patients with chronic hepatitis B, particularly in understanding immune responses and improving therapies.
What benefits are associated with the radiation therapy studied by Dr. Gerety?
The radiation therapy studied may help reduce abnormal tissue growth after bypass surgery for blocked leg arteries, although outcomes like graft blockages still need further research.
How does Dr. Gerety's work impact pediatric health?
His research on hepatitis A helps public health officials and pediatricians understand the exposure rates in children, aiding in vaccination strategies.
Publications in plain English
Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.
2012
Antimicrobial agents and chemotherapy
Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R +1 more
Plain English This study looked at how well inhaled capreomycin, a drug used to treat multidrug-resistant tuberculosis (MDR TB), works in guinea pigs when given in multiple doses. Researchers found that after giving two or three doses, the level of capreomycin in the lungs was 50 to 100 times higher than in the blood, and it remained effective enough to kill the bacteria causing TB. This is important because it shows that inhaled capreomycin could be a more effective way to treat MDR TB without accumulating harmful levels in the lungs.
Who this helps: This benefits patients with multidrug-resistant tuberculosis and their healthcare providers.
Benefits of external beam irradiation for peripheral arterial bypass: preliminary report on a phase I study.
2002
International journal of radiation oncology, biology, physics
Soni AB, Illig KA, Sternbach Y, Anthony P, Jacob P +9 more
Plain English This study investigated the use of targeted radiation therapy after surgical bypass for blocked arteries in the legs to see if it could prevent excessive tissue growth at the surgery site. Out of 21 patients, radiation treatment did not cause any immediate complications, but 12 patients (57%) experienced graft blockages within about 10 months after the procedure. While the radiation seemed to help reduce abnormal tissue growth in some cases, the high rate of blockage indicates that more research is needed to improve outcomes.
Who this helps: This benefits patients undergoing bypass surgery for blocked leg arteries.
Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection.
1987
Journal of hepatology
Pignatelli M, Waters J, Lever A, Iwarson S, Gerety R +1 more
Plain English This study focused on the immune response of T-cells to specific proteins from the hepatitis B virus (HBV) in patients with chronic hepatitis. Researchers found that certain T-cells that attack the virus are present in patients with an active form of the virus but can be blocked by specific antibodies. When these antibodies were given to chimpanzees, they did not prevent infection, but they led to a longer-lasting hepatitis infection, suggesting that these antibodies interfere with the immune response instead of helping it.
Who this helps: This information is important for doctors treating patients with chronic hepatitis B, especially in understanding how their immune systems respond to the virus.
HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection.
1986
Hepatology (Baltimore, Md.)
Pignatelli M, Waters J, Brown D, Lever A, Iwarson S +3 more
Plain English This study looked at the behavior of certain proteins on liver cells during hepatitis B infections. Researchers found that during acute infections, a protein called interferon helps display HLA class I proteins on liver cells, which is important for the immune response. In chronic infections, the presence of HLA class I is low, but giving interferon boosts this display, leading to better outcomes like the clearance of the virus, indicated by specific changes in blood tests.
Who this helps: This benefits patients with hepatitis B, especially those undergoing interferon therapy.
[Hepatitis A of children. Seroepidemiological study among French urban population (author's transl)].
1979
La Nouvelle presse medicale
Drucker J, Coursaget P, Maupas P, Nivet H, Grenier B +1 more
Plain English Researchers studied hepatitis A in 145 children from Tours, France. They found that 34% of the children had antibodies against hepatitis A, indicating past infection, with the rate increasing significantly with age – from 15% in 1 to 5-year-olds to 47% in 11 to 15-year-olds. This matters because it shows that many children are exposed to the virus early in life, often without showing symptoms, which helps inform public health strategies and vaccination efforts.
Who this helps: This helps public health officials and pediatricians understand hepatitis A exposure among children.
Third component, HBeAg/3, of hepatitis B e antigen system, identified by three different double-diffusion techniques.
1978
Journal of clinical microbiology
Murphy B, Tabor E, McAuliffe V, Williams A, Maynard J +2 more
Plain English This study found a new part of the hepatitis B e antigen system, called HB(e)AG/3, using three different testing methods. This new component was consistently identified across all techniques used. Understanding this third component is important because it could improve how hepatitis B is diagnosed and monitored.
Who this helps: Patients with hepatitis B and their doctors.